Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSPCHA131 in advanced solid tumors
NCT04325711Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CSPCHA131 in solid tumor (advanced stage), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum tolerated dose at 28 days, Incidence of Dose Limiting Toxicity at 28 days and 1 more. Status: unknown.
02
Drugs
CSPCHA131
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04325711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04325711.